Pyroptosis Signaling Pathway in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders.
Pyroptosis is a highly inflammatory form of programmed cell death characterized by gasdermin-mediated pore formation on the cell membrane, cell swelling, and release of intracellular contents. Unlike apoptosis, pyroptosis is pro-inflammatory and has been increasingly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)[@nlrp2017].
The discovery of pyroptosis has revolutionized our understanding of cell death in the nervous system. Originally described in immune cells, pyroptosis is now recognized as a critical mechanism in neurons and glia that contributes to neuroinflammation and progressive neuronal loss. The pathway represents a promising therapeutic target, as its inhibition may prevent both cell death and the associated inflammatory response that drives disease progression.
Pyroptosis is executed by a sophisticated molecular machinery involving pattern recognition receptors, adaptor proteins, caspases, and the gasdermin family of pore-forming proteins. Each component plays essential roles in detecting danger signals, assembling the inflammasome complex, activating inflammatory caspases, and executing membrane pore formation.
The canonical pyroptosis pathway is initiated by pattern recognition receptors (PRRs) that detect damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)[@nlrp2017]:
| Component | Type | Function | Reference |
|---|---|---|---|
| NLRP3 | Sensor | Recognizes DAMPs and PAMPs | [@nlrp2017] |
| AIM2 | Sensor | Recognizes cytoplasmic DNA | - |
| ASC | Adaptor | Links sensors to caspase-1 | [@asc2019] |
| Caspase-1 | Effector | Processes pro-IL-1β, pro-IL-18, gasdermin D | [@caspase2016] |
| Gasdermin D | Pore former | N-terminal domain forms pores | [@gasdermin2020] |
| IL-1β | Inflammatory cytokine | Pyroptotic outcome | [@nlrp2016] |
| IL-18 | Inflammatory cytokine | Pyroptotic outcome | - |
Beyond the canonical pathway, several alternative routes to pyroptosis have been identified[@gasdermin2020]:
| Pathway | Trigger | Effector Caspase | Gasdermin |
|---|---|---|---|
| Caspase-4/5/11 | Intracellular LPS | Caspase-4/5/11 (human) | Gasdermin D |
| Caspase-3 | Apoptotic signals | Caspase-3 | Gasdermin E (GSDME) |
| Caspase-8 | Death receptor | Caspase-8 | Gasdermin D (alternative) |
The non-canonical pathways expand the relevance of pyroptosis beyond classical inflammasome activation, connecting pyroptosis to apoptosis (via GSDME) and extrinsic cell death pathways (via caspase-8).
The gasdermin family comprises six members in humans, each with distinct expression patterns and functions[@gasdermin2019]:
| Protein | Expression | Pore Formation | Neuronal Expression |
|---|---|---|---|
| GSDMA | Epithelial cells | Yes | No |
| GSDMB | Epithelial/immune | Yes | No |
| GSDMC | Immune cells | Yes | Limited |
| GSDMD | Ubiquitous | Yes (canonical) | Yes |
| GSDME/DFNA5 | Ubiquitous | Yes (caspase-3) | Yes |
| GSDMF/DFNB59 | Neurons | Yes | Yes (specific to neurons) |
GSDME (also known as DFNA5) is particularly relevant to neurodegeneration as it bridges apoptosis and pyroptosis — caspase-3 cleavage converts the default apoptosis pathway to a pyroptotic one. GSDMF is uniquely expressed in neurons, suggesting specialized pyroptotic mechanisms in the nervous system.
The NLRP3 inflammasome is the most well-characterized sensor in neurodegenerative contexts[@inflammasome2014]:
In neurodegenerative diseases, multiple danger signals converge to activate the NLRP3 inflammasome:
Alzheimer's Disease
Parkinson's Disease
ALS
The molecular mechanism of gasdermin-mediated pore formation has been elucidated[@gasdermin2019]:
The pore formation is a deliberate execute mechanism — the N-terminal fragment has binding specificity for membranes, ensuring the cell rupture is targeted and the inflammatory contents are released.
In Alzheimer's disease, amyloid-beta plays a dual role as both the initiating pathological protein and an activator of the pyroptotic cascade[@inflammasome2014]:
The relationship between pyroptosis and tau pathology is bidirectional and amplificationary[@nlrp32018]:
| Target | Approach | Agent | Status |
|---|---|---|---|
| NLRP3 | Inhibitor | MCC950 | Preclinical/Phase I |
| NLRP3 | Inhibitor | Dapansutrile | Phase II |
| Caspase-1 | Inhibitor | VX-765 | Phase II |
| IL-1β | Receptor antagonist | Anakinra | Clinical trials |
| IL-1β | Antibody | Canakinumab | Clinical trials |
| Gasdermin D | Inhibitor | Disulfiram | Repurposing |
| Gasdermin D | Inhibitor | Dimethyl fumarate | Repurposing |
In Parkinson's disease, alpha-synuclein aggregates represent a major DAMP that activates the NLRP3 inflammasome[@microglial2020]:
The link between mitochondrial dysfunction and pyroptosis is particularly relevant in PD[@parkinson2021]:
The G2019S LRRK2 mutation, the most common genetic cause of PD, promotes NLRP3 activation:
ALS presents with particularly prominent pyroptotic features[@pyroptosis2020a]:
Non-cell autonomous toxicity through astrocytes is a key feature of ALS:
TDP-43 proteinopathy in ALS activates pyroptosis:
In multiple sclerosis, pyroptosis contributes to oligodendrocyte death and demyelination:
NLRP3 Inflammasome Inhibitors
Caspase-1 Inhibitors
Gasdermin Inhibitors
Multiple clinical trials are investigating pyroptosis-targeting approaches in neurodegenerative diseases, with IL-1 blockade being the most advanced. NLRP3-specific inhibitors are advancing through Phase I/II trials.